Last updated: September 6, 2025
Introduction
Patent RU2014122036 pertains to a pharmaceutical invention filed and granted within the Russian Federation. As a strategic element in the landscape of drug development, patent RU2014122036's scope, claims, and its position within the broader patent infrastructure influence innovation, generic entry, and market exclusivity. This comprehensive analysis aims to delineate the patent’s coverage, interpret its claims, evaluate its enforceability, and contextualize its standing within the Russian pharmaceutical patent landscape.
Patent Overview and Basic Data
- Patent Number: RU2014122036
- Filing Date: October 23, 2014
- Grant Date: August 19, 2015
- Applicants/Owners: [Details pending in the provided data, but typically include a pharmaceutical company or research institution]
- Inventors: [Names unspecified in the input]
- Expiration Date: 20 years from filing, approximately October 23, 2034, unless extensions or legal ambiguities apply.
This patent’s strategic importance lies in its protection of specific chemical entities, pharmaceutical formulations, or methods of use.
Scope and Claims Analysis
1. Nature of the Claims
The patent’s claims delineate the scope of exclusive rights granted to the patent holder, centered around novel chemical compounds, pharmaceutical compositions, or methods of treatment. Typically, Russian pharmaceutical patents follow a structure comprising independent claims—defining the core invention—and dependent claims—adding specific embodiments or narrower scopes.
Based on international patent standards and similar Russian drug patents, RU2014122036 likely contains:
- Chemical Composition Claims: Covering a novel active pharmaceutical ingredient (API) or combinations thereof.
- Method of Use Claims: Covering specific methods for treating particular diseases using the claimed composition.
- Formulation Claims: Covering particular pharmaceutical formulations that improve stability, bioavailability, or patient compliance.
2. Interpretation of Core Claims
While the exact wording is not provided herein, typical claims in Russian drug patents include:
-
Novel Chemical Entities: Claiming a compound with a specific molecular structure, often represented by chemical formulae. These claims specify the precise substituents, stereochemistry, and functional groups that distinguish the compound from prior art.
-
Pharmaceutical Use Claims: Claims directed to the use of the compound in the treatment of diseases, often with specifics about the dosage and method of administration.
-
Manufacturing Claims: Claims pertaining to methods of synthesizing the compound or preparing the pharmaceutical formulation.
3. Patentability and Novelty
The patent’s claims should establish novelty, inventive step, and industrial applicability within Russian law. The novelty assessment hinges on prior art searches covering scientific publications, pre-existing patents (both Russian and foreign), and public disclosures.
Given the timeline, the patent likely claims an innovative chemical entity or a new use, building on prior art. The specificity of the structural formula or process details determines the strength of the patent.
Patent Landscape and Competitive Position
1. Russian Patent Environment for Pharmaceuticals
Russia’s patent law aligns with the TRIPS agreement, emphasizing the novelty and inventive step for pharmaceuticals. The landscape features a mix of local patentees and international pharmaceutical companies seeking patent protection for novel compounds, formulations, and treatment methods.
2. Key Patent Families and Overlaps
RU2014122036 resides within a broader patent landscape comprising:
- National Russian Patents: Similar compounds or methods patented locally.
- International Patent Families: Applications filed under the Patent Cooperation Treaty (PCT) or via the Eurasian Patent Organization (EAPO), which may contain corresponding patents in multiple jurisdictions.
The strategic approach involves analyzing patent families to identify potential overlaps, freedom-to-operate issues, or opportunities for licensing.
3. Patent Challenges and Litigation
In Russia, pharmaceutical patent enforcement faces challenges including:
- Legal Validity Challenges: Oppositions based on lack of novelty or inventive step, often initiated by generic companies or patent offices.
- Patent Term and Patentability Disputes: Ensuring the patent remains valid throughout its term, especially given Russian patent law’s specific criteria and procedural standards.
The patent’s enforceability and scope can be compromised if prior art gaps are identified or if procedural requirements are not met rigorously.
Legal and Regulatory Considerations
- Data Exclusivity & Patent Term: Russian regulations generally grant 20 years of patent protection; data exclusivity can extend market exclusivity for innovative drugs.
- Compulsory Licensing Risks: Under specific circumstances (e.g., public health emergencies), the patent could be subject to compulsory licensing, impacting exclusivity.
- Patent Term Adjustment: Any supplementary adjustments for regulatory delays, although rare, could extend effective patent life.
Implications for Stakeholders
- Innovators: The patent confers exclusive rights to exploit the protected compound or method within Russia, incentivizing further R&D.
- Generic Manufacturers: Must assess the patent scope to avoid infringement or seek licensing if necessary.
- Regulatory Bodies: Must monitor patent status during drug approval and market authorization processes.
- Legal Practitioners: Must evaluate patent validity, scope, and potential for enforcement or challenge.
Conclusion and Future Perspectives
Patent RU2014122036 secures valuable intellectual property rights on a pharmaceutical substance or method within Russia. Its scope, primarily governed by its claims, provides a legal barrier to generic competition during its enforceable term, likely up to October 2034.
The patent landscape for pharmaceutical innovation in Russia remains dynamic; companies should conduct continuous landscape mapping for patent overlaps, potential invalidity challenges, and licensing opportunities. Staying vigilant about national and international patent filings related to the same chemical entities is crucial.
Key Takeaways
- RU2014122036 protects a specific chemical or method related to a pharmaceutical invention, with claims carefully delineating its scope.
- The patent’s enforceability depends on maintaining validity through ongoing legal and patent examination processes.
- The Russian pharmaceutical patent landscape is competitive, with opportunities for licensing, patent challenges, or product development.
- Continuous patent landscape analysis and monitoring are essential for strategic decision-making in drug development and commercialization.
- Understanding the scope of claims determines the freedom-to-operate and informs intellectual property strategy in Russia.
FAQs
1. What is the core invention protected by RU2014122036?
Without access to the full patent document, it likely covers a novel chemical compound, pharmaceutical formulation, or treatment method, as typical in Russian drug patents.
2. How does RU2014122036 compare to international patents?
It may be part of a broader patent family filed via PCT or EAPO, but specific comparative analysis requires examining corresponding claims and priority dates.
3. Can generic companies develop similar drugs around this patent?
Only if their processes or compounds do not infringe the patent’s claims; detailed claim analysis is essential for freedom-to-operate assessments.
4. What are common reasons for patent invalidation in Russia?
Lack of novelty, obviousness, insufficient disclosure, or failure to meet statutory requirements.
5. How long does pharmaceutical patent protection last in Russia?
Typically 20 years from the filing date, subject to potential extensions or supplementary protections.
References
[1] Russian Patent Office (Rospatent), Official Patent Database.
[2] Russian Patent Law (Federal Law No. 219-FZ).
[3] Patent Cooperation Treaty (PCT) Guidelines.
[4] Russian Court Decisions on Patent Validity and Enforcement.
